Skip to main content
Equibles
ACH logo

ACH · Accendra Health Inc/Va/

Track ACH — free

Use ACH with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ACH

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.20 -0.11 (-8.40%) At close · Aug 21
Market Cap
$100.75M
Shares
76.90M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.20 Open$1.28 Day$1.18–1.31 52W close$0.95–5.62 Avg vol 30d1.5M Short int5.3M · 6.9% float · 12.6d Short vol65% Last earningsAug 10, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 10

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Strong Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 15.1 · calm Equity put/call 0.58
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −56%
      below
      Price vs 50-day avg −58%
      below
      RSI (14) 28
      oversold
      MACD trend Negative
      52-week position 5%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −62%
      trailing
      6-month return −49%
      trailing
      YTD return −57%
      this year
      Relative strength −61%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $3 › 200d $3 — 50d above 200d
      Institutional flow Distributing
      -3% holders QoQ · +20 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      6.92% of float · ▼ -4.3% MoM · 12.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      139 holders — near 3-yr low, contrarian setup
      Squeeze score 58
      elevated · 0–100
      Fundamentals
      Weak
      Revenue growth +3%
      Y/Y
      Gross margin 80%
      expanding
      EPS growth −203%
      Y/Y
      Free cash flow $-29.5M
      Buyback $100.0M
      authorized
      Balance sheet $954.0M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 98%
      annualized · 1-yr
      Max drawdown −83%
      past year
      ATR 22.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 1 of last 3
      Latest guidance · from the 8-K filed Aug 10, 2026
      full year 2026
      Revenue Initiated $2.45B – $2.55B
      prior FY $2.76B midpoint −9.5% Y/Y
      Full Year 2026
      Adjusted EBITDA Initiated $300M – $320M
      Interest Expense Initiated $142M – $146M
      Prior guidance period ended · from the 8-K filed Oct 30, 2025
      Adj. Effective Tax Rate · Full Year 2025 29.5% – 30.5%
      Guided vs delivered · last 3 settled
      Revenue Full Year 2025
      guided $2.76B – $2.82B
      $2.76B In line
      Net revenue full year 2024
      guided $10.5B – $10.9B
      $2.68B Miss −75.0%
      Full year revenue full year 2023
      guided $10.3B – $10.4B
      $2.55B Miss −75.3%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 3 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −56% Bearish
      Price vs 50-day avg
      −58% Bearish
      RSI (14)
      28 Neutral
      MACD trend
      Negative Bearish
      52-week position
      5% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $3 › 200d $3 — 50d above 200d
      Institutional flow Distributing
      -3% holders QoQ · +20 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      6.92% of float · ▼ -4.3% MoM · 12.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      139 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      Range low $1 Now $1 · 5% Range high $6
      vs 200-day avg -56% vs 50-day avg -58%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      (Loss) income from continuing operations, net of tax, adjusted (non-GAAP) (Adjusted Net (Loss) I non-GAAP -$17.41M Six Months Ended June 30, 2026 —
      Active Patients 2.9M FY25A —
      Commercial Payor Contracts 2,500 FY25A —
      DSO 17.8 the quarter ended June 30, 2026 filing —
      Interest paid -$79M Six Months Ended June 30, 2026 —
      Net debt (non-GAAP) non-GAAP $1.71B June 30, 2026 —
      Patient service equipment capital expenditures -$44M Three Months Ended June 30, 2026 —
      (Loss) income from continuing operations, net of tax, adjusted (non-GAAP) (Adjusted Net Income) non-GAAP -$3.15M Three Months Ended March 31, 2026 —
      Adj. net (loss) income from continuing operations per share, Non-GAAP non-GAAP -$0.04 1Q26 —
      Adj. net (loss) income from continuing operations, Non-GAAP non-GAAP -$3.1M 1Q26 —
      Adjusted EBITDA from continuing operations non-GAAP $375M Year Ended December 31, 2025 —
      Total Adjusted EBITDA non-GAAP $424M Year Ended December 31, 2025 —
      Adj. net income from continuing operations per share, Non-GAAP non-GAAP $0.21 4Q25 —
      Adj. net income from continuing operations, Non-GAAP non-GAAP $16.7M 4Q25 —
      Operating cash flow $154M Full Year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Distribution — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ACH
      Accendra Health Inc/Va/
      this stock
      		$100.75M -57.1% +3.1% — 6.9%
      MCK
      Mckesson Corp
      		 $100.88B +4.7% +3.1% 23.2 3.1%
      COR
      Cencora, Inc.
      		 $60.05B -5.8% +9.3% 23.4 2.7%
      CAH
      Cardinal Health Inc
      		 $53.13B +11.7% +14.2% — 2.8%
      HSIC
      Henry Schein Inc
      		 $9.88B +17.1% +5.9% 25.9 5.7%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      139
      % held
      82.9%
      Net QoQ
      -269.9K sh
      Top holder
      Coliseum Capital Manageme…
      Held Float
      View
      Held by Funds
      Fund positions
      153
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      5.3M
      Days to cover
      12.6d
      Change
      -240.3K sh
      View
      Short Volume
      Short vol %
      65%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      124
      Value
      $430
      As of
      Jul 20, 2026
      View
      Off-Exchange
      Off-exchange %
      47.2%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $2.8B
      Net income (FY)
      $-1.1B
      EPS diluted
      $-14.31
      View
      Buybacks
      Authorized
      $100.0M
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 17, 2026
      This year
      16
      View
      Proposed Sales
      Value
      $62.4K
      Shares
      5.3K
      Filed
      Nov 21, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 10, 2026
      View
      Investor Relations
      Latest news
      Accendra Health Updates on Capita…
      Published
      Aug 17, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ACH +26.3% -61.8% -48.9% -61.2% -57.1%
      SPY -1.4% +3.6% +11.6% +2.5% +12.3%
      vs SPY +27.7% -65.4% -60.5% -63.7% -69.4%

      Capital returns

      Latest dividend
      $0.003 / share · ex Dec 14, 2021
      Paid (TTM)
      $0.00 / share · 0 payouts
      Dividend yield (TTM, derived)
      — · no payout in the trailing year
      Buyback program · as of Feb 26, 2025
      Authorized
      $100.00M
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 75252 CUSIP 690732102 13F (30d) 126 filings 126 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)